Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Pancreatic
Skin
Breast
SOLID CANCERS
Lung
Prostate
Brain
LIQUID CANCERS
Leukemia Hodgkins Non-Hodgkins
CRESCITA DELLA MASSA NEOPLASTICA Divisioni cellulari No. Di cellule Peso (g)
PROCESSO DI CANCEROGENESI
TOSSICOCINETICA E METABOLISMO DANNO E RIPARO DEL DNA INIZIAZIONE (giorni - settimane)
Dose espositiva Dose farmacologica Dose cellulare Dose bersaglio Dose molecolare
STRATEGIE DI INTERVENTO
0 5 10 15 20 25 30 35 40
10 0 10 1 10 2 10 3 10
4
PREVENZIONE PRIMARIA
10 5 10 6 10 7 10 10
8 9
PROGRESSIONE (~ 1 anno)
CANCRO
PREVENZIONE SECONDARIA
C H E M I O P R E V E N Z I O N E
1010 1011 10 12
INVASIONE
2 3
METASTASI
MASSA NEOPLASTICA
Espressione di Cx43
Controlli / DMBA
Differenze significative DMBA vs. controlli S. De Flora et al., Int. J. Oncol., 29, 521529, 2006
Espressione di Cx43
Controlli / DMBA
Differenze significative DMBA vs. controlli S. De Flora et al., Int. J. Oncol., 29, 521529, 2006
Phase II
NAT2 NAT1 GST-M GST-T GST-P GST-A
CYP2O6 CYP3A4/5/7
Drug-metabolizing enzymes known to exhibit common polymorphisms at the genomic level that have been associated with changes in drug effects; however, almost every gene involved in the drug metabolism is subject to common genetic polymorphisms that may contribute to interindividual variability in drug response and drug toxicity.
Bay region
10 9 8
11
Benzo[a]pyrene
K region
Mono- oxygenase
O
Simple epoxides
O 9,10Oxide 7,8Oxide 4,5Oxide O
Epoxide hydratase
OH HO HO 9,10Dihydrodiol OH 7,8Dihydrodiol OH 4,5Dihydrodiol OH
Dihydrodiols
Mono-oxygenase
OH HO HO O 9,10Diol7,8oxide OH 7,8Diol9,10oxide O
Diol- epoxides
GLUCOSO GLUCOSE
NADPH
GSSG
GSSG
2H2 O 2
G6P
G6PD
6PGD 6PG
REDUTTASI REDUCTASE
NADP + H+
2 GSH
O2 H2 2 2
postlabelled DNA adducts Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Spot 6 Spot 7 Spot 8 Spot 9 DRZ Total
GSTM1+ (n = 36) 0.46 0.11 0.23 0.10 0.13 0.26 0.36 0.25 0.64 10.80 13.80 0.63 0.25 0.49 0.18 0.35 0.27 0.48 0.35 1.07 6.16 9.77
GSTM1 (n = 39) 0.58 0.74 0.20 0.28 0.51 0.74* 0.28 0.43 0.28 0.57** 0.46 0.52 0.86 1.23* 0.77 1.40** 2.74 5.97** 16.41 10.63** 22.67 18.63**
Ratio (/+) 1.3 1.8 2.2 2.8 2.2 1.8 2.4 3.1 4.3 1.5 1.6
CHROMIUM(VI) REDUCING CAPACITY OF ORGANS, CELL POPULATIONS AND FLUIDS IN THE HUMAN DIGESTIVE SYSTEM
SALIVA [0.7 2.1 mg Cr(VI)/day]
ELF [0.9 1.8 mg Cr(VI)] PAM [136 mg Cr(VI)] BLOOD [187 234 mg Cr(VI)] LIVER CELLS [3,300 mg Cr(VI)]
THRESHOLDS IN CARCINOGENESIS?
CARCINOGENESIS PROCESS
TOXICOKINETIKS AND METABOLISM DNA DAMAGE AND REPAIR INITIATION (days - weeks)
Exposure dose Pharmacologic dose Cellular dose Target dose Molecular dose
DNA repair
Apoptosis
BENIGN TUMOR
PROGRESSION (~ 1 year)
CANCER
INVASION
METASTASIS
NEOPLASTIC MASS
CARIOTIPO UMANO
CORRELAZIONE FRA
C
MUTAGENICITA E CANCEROGENICITA
Ames reversion test NG
Accuracy = 74.7% (68/91)
20.7% (12/58)
DNA-repair test
Accuracy = 73.7% (59/80)
NG 40.9% (9/22)
EFFETTI PATOLOGICI DELLE MUTAZIONI NELLUOMO MUTAZIONI IN CELLULE SOMATICHE (in et adulta o in epoca embrionale)
Sterilit, aborto, morte perinatale (mutazioni dominanti letali) Malattie genetiche nei neonati (mutazioni dominanti non letali) Malattie genetiche in generazioni successive (mutazioni recessive)
AGEING
mtDNA
nDNA
NAC +
XP AT AF Suscettibilit individuale
UV Light
R hH B 23
TF IIH
C S B
X PX CP
A
C S A
NER
Br X- eak b Ra ys y P
G1
ellll C Ce c yc C Cy e lle
PN K
S
RNA Pol UV & Bulky Adducts
TF IIH
X P D
XA B2
X P B
X P G
DNA-Damage Checkpoint
G2
R P A
ERC C1
NER
X P F
B DS
Ku70 /80
BRC A1
IG F1
Ra d52
D DN NA A-D Da am m a ag ge e C Ch he ec k kp c po oiin n tt
BAR D1
BRC A2 P
P
om H
M
p 5 3 Chk 2 Chk 1
70 Ku 0 /8
MR E11
C P BR A1
JNK/SA PK
D45 GAD
Apoptosis
ir pa Re
PC NA
ads NA Lo -P n to D RF o NA PC
Lig ase
PC NA
xo O
Abasic Site
B B E E R R
Po l- SN M1
/
DN Po A l
Pol-
Hu s1
U b U U b bU b
MD M2 p 5 3
PC Proo f NA Readin g
FE N1
Proteas ome
BER
Cell Proliferation
M S H 6
MS H2
hOG G1
TRE X1
E TR X2
AP E1
MM R
MS H2
MS H3
M M u u tt S S
M M u u tt S S
G
R BE
hN TH
Me
5
U BER
3
MB D4
UN G2 SMU G1
Nucleus
2009 2009 ProteinLounge.com ProteinLounge.com
C
O2
e
ANIONE SUPEROSSIDO
H2O2
e
IDROGENO PEROSSIDO
OH
e
RADICALE IDROSSILE
H2O
O2
OSSIGENO MOLECOLARE
Luce coloranti
O2
OSSIGENO SINGOLETTO
ORGANOSPECIFICITA DEI PROMOTORI TPA NaCl Saccarina Componenti della bile Estrogeni Fenobarbital Componenti del fumo Cute Stomaco Vescica Colon Mammella Fegato Polmone
CRESCITA DELLA MASSA NEOPLASTICA Divisioni cellulari No. Di cellule Peso (g)
PROCESSO DI CANCEROGENESI
TOSSICOCINETICA E METABOLISMO DANNO E RIPARO DEL DNA INIZIAZIONE (giorni - settimane)
Dose espositiva Dose farmacologica Dose cellulare Dose bersaglio Dose molecolare
STRATEGIE DI INTERVENTO
0 5 10 15 20 25 30 35
10
10
-9
10 1 10 2 10 3 10
4
PREVENZIONE PRIMARIA
10 5 10 6 10 7 10 10
8 9
PROGRESSIONE (~ 1 anno)
CANCRO
PREVENZIONE SECONDARIA
1010 10 40
11
INVASIONE
2 3
METASTASI
10 12
MASSA NEOPLASTICA
ANGIOGENESI E ANTIANGIOGENESI
ANGIOGENESI E LINFANGIOGENESI
VEGF Pathway
PIP2
ell lC lia e h dot En
PIP2
SHC FAK
Paxillin
P
eNOS BAD
P
HSP90 Caspase9
MAPKAPK2/3 MAPKAPK2/3 Cell Migration HSP27 Nitric Oxide Production cPLA ERK1/2 Actin Actin Reorganization Reorganization Gene Expression & Cell Proliferation ANGIOGENESIS Vascular Cell Permeability
MEK1/2
Cell Survival
2009 ProteinLounge.com
C
IL CICLO CELLULARE
2009 ProteinLounge.com
C
TGF
p19(INK4D)
GS K3
CDC25A
P
p ( K 27 IP1 ) C CIIP P //K F KI Fa am P miil IP ly y
ATR
D DN NA AD Da am ma ag ge e
CDK4/6 CyclinD/D1
K1 CD
Ubiquitination Ubiquitination
P
Cyclin-E CDK2 P P P Rb
1 W ee
G1
Ubiquitination Ubiquitination
Cyc
lin-A
K1 CD
P Rb E2F
HDACs
DP1
P Off Off On On
DP1
P P Cyclin-H
PP2A
Nucleus
Cell Cell Cycle Cycle Progression Progression Cyclin-H
A
MYT1
Wee1
CDC
25A
E 2F
Cyc
B lin-
E2F P
1 We e
Rb P Rb P
lin-A
S-Phase S-Phase Genes Genes [Cyclin-A, [Cyclin-A, E,E2F, E,E2F, CDC2] CDC2]
E2F
P p21
K1 CD
linCyc
CDK7 P P P P
Rb
Rb
Wee
2 CDK
Cyc
p21
lin-A Cyc
p CDK2 (K 27 IP1 P )
CDC25A
K1 CD P P
P Raf1
A C25 CD
G2
MYT1
SCF Ub SCF
Ub
Ub
PROTOONCOGENI
ONCOGENI
TRASLOCAZIONE CROMOSOMICA
MUTAZIONI PUNTIFORMI
AMPLIFICAZIONE GENICA
GENI ONCOSOPPRESSORI
Hypoxia Hypoxia
UV UV
Chemotherapy Chemotherapy
p53 Signaling
F a s
D R 5
JNK
HIPK2
CSNK1
p38
Proteasome Proteasome Hypoxia Induced Hypoxia Induced HIF1 HIF1 Expression Expression PTEN p53 HIF1 P p53 P ATR
DNA DNA Damage Damage Apoptosis Apoptosis ATM P P Chk2 DNA-PK BRCA1 Cell Cell Survival Survival PCAF CAK Ac p53 Ac p53 P P PTEN GSK3 Akt Caspase Bax
Ub Ub p53 MDM2
Ub
c-Abl Ac HDAC p53 p300 Sirt p21CIP MDM2 CyclinD1 CDK2 E2F Rb CyclinE CDK4 Cell Cell Cycle Cycle Progression Progression
C
BCL2 Gene Gene Expression Expression DNA DNA Repair Repair TSP1 BAI1 c-Fos GADD45 P Rb Angiogenesis Angiogenesis Inhibition Inhibition
14-3-3
E2F
2009 ProteinLounge.com
2009 ProteinLounge.com
Apo2L / Apo3L
TNF TNFR1
FasL
Fas
D FA e sD aspa c o r P 8
Apo2/ Apo3
T AD R
D FA Procaspase8 D
RIP TRAF2
DD Procaspase8
FA
TR A D D
PKC p90RS K
BID FLIP CIAP1 SMAC Caspase9 Arts APAF 1 HTRA 2 Cytoc Apoptosis EndoG POD POD 4 PML PAR ZIPK Daxx CAD AT M NF-B Chk2 Endo G tBI BCLXLD MMP IKKs IB NF-B
BAX
BAK
ICAD CAD
Apoptosis
Noxa AIF
PUMA
PARP
DN AIF Fragm A entati on FLIP,CIAP2,BFL1, FLIP,CIAP2,BFL1, BCL2 BAK,BAK,BID, BCL2 Ras,Noxa,PUMA, p53 APAF1,Survivin, BCL2 MDM2 p53
Mit oc h dr i on a
BCL2
BIM
1 AI P 3 p5
Depolarization Oncogenic Signal p14(ARF)
LOSS OF FHIT EXPRESSION IN SPRAGUE-DAWLEY RATS EXPOSED TO CIGARETTE SMOKE FOR 28 DAYS
1.4 0.74% 4.9 1.96%
P < 0.001 compared to SHAM
3.1 1.7%
P < 0.05 compared to ECS
Bronchial epithelium
1.1 0.64%
1.4 0.52%
1.3 0.71%
SHAM
ECS
ECS + NAC
Colorectal carcinogenesis: adenomacarcinoma sequence. (Adapted from Kelloff GJ, Hawk ET, Crowell J, et al: Oncology 10(10):147184, 1996 and Ilyas M, Straub J, Tomlinson IP, et al: Eur J Cancer 35:33551, 1999 and reprinted with permission (131, 132).